MktsMarkets

Foghorn Therapeutics Inc.
NASDAQ: FHTXKey statistics
FHTX News
Stories mentioning FHTX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 3,267 | 9,247 | 8,153 | 7,557 | 5,952 | 2,856 | 7,808 | 6,888 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 18,259 | 22,046 | 20,002 | 21,792 | 21,626 | 20,508 | 24,689 | 23,797 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 24,840 | 33,125 | 26,654 | 28,654 | 28,865 | 26,861 | 31,660 | 33,520 |
| Operating Income (Loss) | (21,573) | (23,878) | (18,501) | (21,097) | (22,913) | (24,005) | (23,852) | (26,632) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (19,503) | (19,122) | (22,979) | |||||
| Tax Provision | 0.00 | 0.00 | 0.00 | |||||
| Net Income (Loss) | (19,875) | (21,664) | (15,849) | (17,936) | (18,834) | (19,503) | (19,122) | (22,979) |
| Earnings Per Share (Basic) | (0.29) | (0.34) | (0.25) | (0.28) | (0.30) | (0.36) | (0.31) | (0.45) |
| Earnings Per Share (Diluted) | (0.29) | (0.34) | (0.25) | (0.28) | (0.30) | (0.36) | (0.31) | (0.45) |
| Weighted Average Shares Outstanding (Basic) | 69,540 | 62,981 | 63,029 | 62,978 | 62,849 | 54,899 | 62,603 | 51,580 |
| Weighted Average Shares Outstanding (Diluted) | 69,540 | 62,981 | 63,029 | 62,978 | 62,849 | 54,899 | 62,603 | 51,580 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About FHTX
Foghorn Therapeutics Inc. (NASDAQ: FHTX) is a stock listed on the Nasdaq Stock Market under the ticker symbol FHTX. It last traded at $2.07 (Nov 9, 2026, 9:30 AM ET), up 10.7% on the day. That gives Foghorn Therapeutics a market capitalisation of $111.1M.
Over the past 52 weeks FHTX has traded between $1.79 and $7.61.
Revenue for the quarter ended Mar 31, 2026 was $3.3M; a net loss of $19.9M. Revenue was down 45.1% from $6.0M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $3.3M | -$19.9M | -608.4% |
| Dec 31, 2025 | $9.2M | -$21.7M | -234.3% |
| Sep 30, 2025 | $8.2M | -$15.8M | -194.4% |
| Jun 30, 2025 | $7.6M | -$17.9M | -237.3% |
From Foghorn Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…